We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

AMP:ASXAMP Limited Analysis

Data as of 2026-05-27 - not real-time

A$1.60

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

AMP trades at $1.60, just below its 200‑day SMA (1.605) but comfortably above the 20‑day (1.540) and 50‑day (1.420) averages, indicating a short‑term bullish bias. The RSI sits at 69.4, flirting with overbought levels, while the MACD remains marginally bullish, and volume is tapering, suggesting a potential near‑term ceiling around the $1.61 resistance.
Valuation metrics show a trailing P/E of 32 versus an industry average of 16.6, flagging the stock as overvalued on a historical basis, yet a forward P/E of 13.1 points to improving earnings. The company carries an extreme debt‑to‑equity ratio of ~792 and negative operating cash flow, which tempers the attractiveness of its 2.5% dividend yield. Market sentiment is very optimistic (Fear‑Greed Index 92.1, “Extreme Greed”), but the 30‑day volatility of 23% and a beta under 1 underscore heightened price swings. Overall, the upside is modest (~5.8% to the analyst target of $1.69) and the risk profile is weighted toward financial leverage and valuation concerns.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price near resistance at $1.61
  • RSI approaching overbought territory
  • Decreasing volume indicating waning momentum

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Forward P/E of 13.1 suggests earnings improvement
  • Analyst target price of $1.69 implies ~5.8% upside
  • Stable 2.5% dividend yield with payout ratio below 60%

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Extremely high debt‑to‑equity ratio increasing financial risk
  • Low ROE (3.6%) and ROA (3.1%) indicating modest profitability
  • Sector stability in Australian financial services with moderate regulatory pressure

Key Metrics & Analysis

Financial Health

Profit Margin4.76%
P/E Ratio32.0
ROE3.60%
ROA3.11%
Debt/Equity791.59
P/B Ratio1.1
Op. Cash FlowA$-1375000064
Free Cash FlowA$150.2M
Industry P/E16.6

Technical Analysis

TrendNeutral
RSI69.4
SupportA$1.41
ResistanceA$1.61
MA 20A$1.54
MA 50A$1.42
MA 200A$1.61
MACDBullish
VolumeDecreasing
Fear & Greed Index92.11

Valuation

Target PriceA$1.69
Upside/Downside5.75%
GradeOvervalued
TypeBlend
Dividend Yield2.50%

Risk Assessment

Beta0.71
Volatility23.02%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.